Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases
Year: 2015
Type: review
Abstract: Neurodegenerative diseases are a leading cause of death.No diseasemodifying therapies are available, and preclinical animal model data have routinely failed to translate into success for therapeutics.Induced pluripotent stem cell (iPSC) biology holds great promise for human in vitro disease modeling because these cells can give rise to any cell in the human brain and display phenotypes specific to neurodegenerative diseases previously identified in postmortem and clinical samples.Here, we explore the potential and caveats of iPSC technology as a platform for drug development and screening, and the future potential to use large cohorts of disease-bearing iPSCs to perform clinical trials in a dish.489 Click here to view this article's online features: • Download figures as PPT slides • Navigate linked references • Download citations • Explore related articles • Search
Authors: Kelly M. Haston, Steven Finkbeiner
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funders: National Science Foundation, Michael J. Fox Foundation for Parkinson's Research, California Institute for Regenerative Medicine, ALS Association, Roddenberry Foundation, Hellman Family Foundation, National Institutes of Health, National Institute of Mental Health, National Human Genome Research Institute, National Institute of Neurological Disorders and Stroke
Awards: Mechanisms of Neuromuscular Repair by Schwann Cells, G2659049673, Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells, Physical Exam of Human Neurons to Identify Functions of the Druggable Genome, The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development, G3806279549, G4193422873, Mechanisms of Huntingtin-induced Neurodegeneration, Automated longitudinal single cell analysis
OpenAlex ID: W1829807625
